PeptideInjectable peptideAmylin analogue

Cagrilintide

Also known as AM833 · Component of CagriSema

Written by enwyReviewed 15 Jul 20261 sources0 comments

Cagrilintide is a long-acting amylin analogue given once weekly for weight management. It is most studied in combination with semaglutide (as CagriSema), where the pairing produces greater weight loss than either agent alone. As monotherapy and in combination it is in late-stage development but not yet approved.

01 Overview

Cagrilintide is an acylated analogue of amylin, a pancreatic hormone co-secreted with insulin that promotes satiety, slows gastric emptying and reduces food intake. Native amylin has a very short half-life; cagrilintide is engineered for once-weekly subcutaneous dosing. It acts on both amylin and calcitonin receptors.

Most clinical attention has focused on the fixed-dose combination with semaglutide (CagriSema), which pairs amylin and GLP-1 pathways for additive appetite suppression. Phase-2 and phase-3 data show weight loss competitive with the leading incretin drugs. Cagrilintide monotherapy has more limited published data, giving it a moderate human-evidence base overall.

02 Mechanism

Long-acting amylin (and calcitonin) receptor agonist. Reduces appetite and food intake, slows gastric emptying and enhances satiety through pathways complementary to GLP-1, which is why it is frequently combined with semaglutide.

03 Dosing

Tier	Dose	Route	Notes
Starting dose	0.25–0.6 mg/wk	SubQ	Initiation dose before titration.
Maintenance	1.2–2.4 mg/wk	SubQ	Titrated maintenance range in trials, alone or paired with semaglutide 2.4 mg.

04 Effects

Effect	Magnitude	Evidence
Weight lossMeaningful weight loss as monotherapy, substantially greater when combined with semaglutide.	-10% monotherapy; ~-15-22% with semaglutide	Clinical
Appetite suppressionReduced hunger and food intake via amylin-mediated satiety signalling.	reduced ad-libitum intake	Clinical

05 Side effects

Effect	Severity	Frequency	Evidence	Countermeasures
Gastrointestinal upsetNausea, vomiting and constipation, largely during dose escalation and amplified when combined with a GLP-1 agonist.	Moderate	Common during titration	Clinical
Injection-site reactionsLocalised redness or discomfort at the injection site.	Mild	Occasional	Clinical

06 Legal status

United States

Investigational, not approved

Not approved as monotherapy; CagriSema under regulatory review as of 2026. · as of Jan 2026

07 References

Cagrilintide alone and in combination with semaglutide in obesityThe Lancet, 2021

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.